Clinical Trials Logo

Clinical Trial Summary

The concept of trained immunity defines the long-term functional reprogramming of innate immune cells, which is evoked by exogenous or endogenous insults and leads to an altered response towards a second challenge after return to a non-activated state and is characterized by several markers, such as specific cytokines, activation markers of innate immune cells and epigenetic modifications, e.g. H3K4me3. Vaccinations have been shown to induce trained immunity and to have heterologous effects on other infections or vaccinations. A recent article showed, that individuals who had received recombinant adjuvanted zoster vaccine (RZV) before the pandemic had a 16% lower risk of COVID-19 diagnosis and a 32% lower risk of hospitalization suggesting a protective heterologous effect of RVZ on COVID19 infections. So far, the mechanisms behind these add-on benefits of RZV vaccination are on the hypothetical level and need further experimental evidence. Therefore, we aim to investigate the specific humoral and cellular immune response towards COVID-19 vaccine in healthy individuals who were exposed to RZV 1 to 12 months before COVID-19 vaccination compared to individuals who did not receive RZV before. Particular emphasis is layed on COVID-19 vaccine non-responders and individuals with breakthrough infections indicating lower vaccine efficacy compared to those who had no breakthrough infection. The primary objective is the cytokine profile of spike protein-stimulated T, NK and NKT cells. Spike protein stimulated T, NK and NKT cells are characterized by cell surface markers, transcription factor expression, chemokine receptor expression, activation and proliferation markers and by their lineage-specific cytokine pattern. CD14+ monocytes are magnetically isolated and further characterized by cell-culture experiments imitating a training and resting period after stimulation. Epigenetic modifications by methylation of CpG regions are assessed at promoter, enhancer and regulatory gene regions of immune cell characteristic transcription factors by bisulfite conversion and pyrosequencing. Chromatin immunoprecipitation and ChIP-seq will be performed for analysis H3K4me3 associated with trained immunity. Humoral and cellular reactivity to spike protein is analyzed by adapted ELISA and neutralisation assays and by ELISpot and flow cytometry, respectively, and correlated. From our findings we expect to learn about the role of previous RZV on immunogenicity and efficacy of COVID-19 vaccination and whether mechanisms of trained immunity play a role for better responses towards COVID-19 vaccination.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05705180
Study type Observational
Source Wuerzburg University Hospital
Contact Martina Prelog, Prof. Dr.
Phone 093120127708
Email Prelog_M@ukw.de
Status Recruiting
Phase
Start date December 1, 2022
Completion date December 1, 2024

See also
  Status Clinical Trial Phase
Terminated NCT05977127 - Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly Phase 2
Recruiting NCT06048406 - Effect of Health Education on Promoting Influenza Vaccination Health Literacy N/A
Completed NCT03144518 - Mood and Influenza Vaccine Response: A Feasibility Trial N/A
Completed NCT05869201 - Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine Phase 2/Phase 3
Recruiting NCT06088563 - Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX N/A
Completed NCT05160766 - Assessing Immune Response of Different COVID-19 Vaccines in Older Adults Phase 2
Recruiting NCT05222139 - Monitoring COVID-19 Vaccination Response in Fragile Populations
Enrolling by invitation NCT05028881 - COVID-19 Serology in People Living With HIV in Hong Kong
Recruiting NCT05315362 - Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine Phase 2
Not yet recruiting NCT04848441 - Risk of COVID-19 Infection After Vaccination
Recruiting NCT04920357 - Immune Response to Vaccination Against Covid-19, a Follow up Study
Not yet recruiting NCT03880669 - The 6-in-1 Vaccine Study Phase 4
Recruiting NCT05898464 - Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV Phase 4
Not yet recruiting NCT05856396 - Maternal Determinants of Infant Immunity to Pertussis Phase 4
Recruiting NCT05658614 - Anti-Schistosomiasis Sm14-vaccine in Senegal Phase 2
Completed NCT05457894 - Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women Phase 3
Completed NCT05470582 - Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old Phase 3
Recruiting NCT05160428 - Post Covid-19 Vaccination Development or Flare of ARD
Recruiting NCT04970836 - The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort N/A